Sanofi announced that it has entered into exclusive negotiations with the US private equity firm Clayton, Dubilier & Rice (CD&R) to transfer around 50% controlling stake in Opella.

US-based investment firm takes controlling stake in Opella, while France's government moves to ensure the company remains in ...

Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

Sanofi has entered exclusive negotiations to sell a 50% controlling stake in its consumer health business ... Opella, which houses brands including Allegra, generated sales of $5.7 billion ...

Sanofi and CD&R are joining forces to fuel Opella’s ambitions as a French-headquartered, global consumer healthcare ... With a portfolio of iconic brands, such as Allegra, Doliprane and Dulcolax ...

Sanofi first telegraphed plans for a potential consumer health separation last October ... the company is known for popular household brands like the allergy med Allegra, Icy Hot for muscle ...

It also owns the antihistamine brand Allegra and the laxative Dulcolax. "Together, CD&R and Sanofi will support Opella's growth strategy as a pure-play, global and fast-moving consumer health care ...

With a portfolio of brands, such as Allegra ... reportedly raised its bid for Sanofi’s consumer health division by around 200 million euros ($217.12 million). While CD&R has emerged as the ...

Opella employs 11,000 people globally and sells popular French pain medicine Doliprane, as well as brands ... Sanofi, which said a year ago it was reviewing separation scenarios for its consumer ...

that Doliprane — a brand of paracetamol produced by Sanofi — “will continue to be produced in France”. Sanofi’s divestment of its consumer business has sparked a backlash because France ...

Sanofi's consumer health unit, valued at $17.4 billion. Opella serves over 500M consumers globally with top brands like Allegra and Dulcolax. Sanofi SA SNY and private equity Clayton Dubilier ...